ArticlePLoS neglected tropical diseases2015
A DNA vaccine against yellow fever virus: development and evaluation.
Article in PLoS neglected tropical diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 50 citations in OpenAlex.
- The first key for the Priority Pathogens: Protective immunogens in development of vaccines and medications.Biosafety and health · 2026Review
- Review
- Immunomodulatory activity of Trypanosoma cruzi recombinant antigen combination TSA-1-C4 and Tc24-C4 induce activation of macrophages and CD8Parasitology research · 2025Article
- A bivalent self-amplifying RNA vaccine against yellow fever and Zika viruses.Frontiers in immunology · 2025Article
- Advancing molecular modeling and reverse vaccinology in broad-spectrum yellow fever virus vaccine development.Scientific reports · 2024Article
- Development of nucleic acid-based vaccines against dengue and other mosquito-borne flaviviruses: the past, present, and future.Frontiers in immunology · 2024Review
- Enhanced immunogenicity and protective efficacy in mice following a Zika DNA vaccine designed by modulation of membrane-anchoring regions and its association to adjuvants.Frontiers in immunology · 2024Article
- Re-thinking yellow fever vaccines: fighting old foes with new generation vaccines.Human vaccines & immunotherapeutics · 2022Review
- Evaluation of Two Adjuvant Formulations for an Inactivated Yellow Fever 17DD Vaccine Candidate in Mice.Vaccines · 2022Article
- LAMP-1 Chimeric to HIV-1 p55Gag in the Immunization of Neonate Mice Induces an Early Germinal Center Formation and AID Expression.Vaccines · 2022Article
- Vector-Borne Viral Diseases as a Current Threat for Human and Animal Health-One Health Perspective.Journal of clinical medicine · 2022Review
- The Present and Future of Yellow Fever Vaccines.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Pregnant women & vaccines against emerging epidemic threats: Ethics guidance for preparedness, research, and response.Vaccine · 2021Review
- Small-molecule inhibitors of TBK1 serve as an adjuvant for a plasmid-launched live-attenuated yellow fever vaccine.Human vaccines & immunotherapeutics · 2020Article
- Vaccination and Therapeutics: Responding to the Changing Epidemiology of Yellow Fever.Current treatment options in infectious diseases · 2020Review
- Vaccination and Therapeutics: Responding to the Changing Epidemiology of Yellow Fever.Current treatment options in infectious diseases · 2020Review
- Review
- A Single Dose of Modified Vaccinia Ankara Expressing Lassa Virus-like Particles Protects Mice from Lethal Intra-cerebral Virus Challenge.Pathogens (Basel, Switzerland) · 2019Article
- Novel vaccines: Technology and development.The Journal of allergy and clinical immunology · 2019Review
- Development of potent class II transactivator gene delivery systems capable of inducing de novo MHC II expression in human cells, in vitro and ex vivo.Gene therapy · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 2 countries.
Funding
Abstract
Attenuated yellow fever (YF) virus 17D/17DD vaccines are the only available protection from YF infection, which remains a significant source of morbidity and mortality in the tropical areas of the world. The attenuated YF virus vaccine, which is used worldwide, generates both long-lasting neutralizing antibodies and strong T-cell responses. However, on rare occasions, this vaccine has toxic side effects that can be fatal. This study presents the design of two non-viral DNA-based antigen formulations and the characterization of their expression and immunological properties. The two antigen formulations consist of DNA encoding the full-length envelope protein (p/YFE) or the full-length envelope protein fused to the lysosomal-associated membrane protein signal, LAMP-1 (pL/YFE), aimed at diverting antigen processing/presentation through the major histocompatibility complex II precursor compartments. The immune responses triggered by these formulations were evaluated in H2b and H2d backgrounds, corresponding to the C57Bl/6 and BALB/c mice strains, respectively. Both DNA constructs were able to induce very strong T-cell responses of similar magnitude against almost all epitopes that are also generated by the YF 17DD vaccine. The pL/YFE formulation performed best overall. In addition to the T-cell response, it was also able to stimulate high titers of anti-YF neutralizing antibodies comparable to the levels elicited by the 17DD vaccine. More importantly, the pL/YFE vaccine conferred 100% protection against the YF virus in intracerebrally challenged mice. These results indicate that pL/YFE DNA is an excellent vaccine candidate and should be considered for further developmental studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.